Document:

EX-10.13

 Exhibit 10.13 

ARCUS BIOSCIENCES, INC. 

MANAGEMENT CASH INCENTIVE PLAN 

ARTICLE 1. BACKGROUND AND PURPOSE 

1.1 Effective Date. This Plan became effective upon its adoption by the Committee and is not subject to approval by the Company’s
stockholders. 
 1.2 Purpose of the Plan. The Plan is intended to provide Participants with the possibility of earning incentive
bonuses. 
 ARTICLE 2. DEFINITIONS 

The following words and phrases shall have the following meanings, unless a different meaning is plainly required by the context: 

2.1 “Actual Award” means, as to any Performance Period, the actual award amount (if any) payable to a Participant for the
Performance Period. Each Actual Award is determined by the Payout Formula for the Performance Period, subject to the Administrator’s authority under Section 3.6 to increase, eliminate or reduce the award otherwise indicated by the Payout
Formula. 
 2.2 “Administrator” means the Board, Committee or such other entity, group, or individual delegated authority to
administer the Plan in accordance with Section 5.1 of the Plan. 
 2.3 “Affiliate” means any corporation or other
entity (including, without limitation, partnerships and joint ventures) controlled by the Company. 
 2.4 “Base Salary”
means, as to any Performance Period, the Participant’s regular base salary as in effect at the end of the Performance Period. Base Salary shall be calculated before both (a) deductions for taxes or benefits and (b) any deferrals of
compensation pursuant to Company-sponsored plans or Affiliate-sponsored plans. 
 2.5 “Board” means the Company’s Board
of Directors. 
 2.6 “Change in Control” means (a) a sale, conveyance or other disposition of all or substantially all
of the assets, property or business of the Company, except where such sale, conveyance or other disposition is to a wholly owned subsidiary of the Company, (b) a merger or consolidation of the Company with or into another corporation, entity or
person, other than any such transaction in which the holders of voting capital stock of the Company outstanding immediately prior to the transaction continue to hold a majority of the voting capital stock of the Company (or the surviving or
acquiring entity) outstanding immediately after the transaction (taking into account only stock of the Company held by such stockholders immediately prior to the transaction and stock issued on account of such stock in the transaction), or
(c) the direct or indirect acquisition (including by way of a tender or exchange offer) by any 

 
person, or persons acting as a group, of beneficial ownership or a right to acquire beneficial ownership of shares representing a majority of the voting power of the then outstanding shares of
capital stock of the Company; provided, however, that a Change of Control shall not include any transaction or series of related transactions (1) principally for bona fide equity financing purposes or (2) effected exclusively for the
purpose of changing the domicile of the Company. A series of related transactions shall be deemed to constitute a single transaction for purposes of determining whether a Change of Control has occurred. 

2.7 “Committee” means the Compensation Committee of the Board. 

2.8 “Company” means Arcus Biosciences, Inc., a Delaware corporation, or any successor thereto. 

2.9 “Employee” means any employee of the Company or of an Affiliate, whether such employee is so employed when the Plan is
adopted or becomes so employed after the adoption of the Plan. 
 2.10 “Executive” means any executive officers as defined
under Rule 3b-7 and officer as defined under Rule 16a-f promulgated under Section 16 of the Securities and Exchange Act. 

2.11 “Fiscal Year” means the fiscal year of the Company. 

2.12 “Participant” means, as to any Performance Period, an Employee who has been selected for participation in the Plan for
that Performance Period pursuant to Section 3.1. 
 2.13 “Payout Formula” means, as to any Performance Period, the
formula or payout matrix established by the Administrator pursuant to Section 3.5 in order to determine the Actual Awards (if any) to be paid to Participants. The formula or matrix may differ from Performance Period to Performance Period and
from Participant to Participant. 
 2.14 “Performance Period” means a Fiscal Year, or any longer or shorter period
determined by the Administrator. 
 2.15 “Performance Goals” means the goal(s) or combined goal(s) determined by the
Administrator to be applicable to a Participant for a Target Award for a Performance Period. As determined by the Administrator, the Performance Goal(s) may provide for a targeted level or levels or achievement using the performance criteria
specified by the Administrator. Possible performance criteria are set forth in Appendix A attached to the Plan. 
 2.16
“Plan” means this Arcus Biosciences, Inc. Management Cash Incentive Plan, as amended from time to time. 
 2.17
“Shares” means shares of the Company’s common stock. 
 2.18 “Target Award” means the target award
amount payable under the Plan to a Participant for the Performance Period expressed as a percentage of his or her Base Salary or a specific dollar amount or by reference to a number of Shares, as determined by the Administrator in accordance with
Section 3.4. 

  
 2 

 2.19 “Termination of Employment” means a cessation of the employee-employer
relationship between an Employee and the Company or an Affiliate for any reason, including (without limitation) a termination by resignation, discharge, death, disability, retirement or the disaffiliation of an Affiliate, but excluding a transfer
from the Company to an Affiliate or between Affiliates. 
 ARTICLE 3. SELECTION OF PARTICIPANTS AND DETERMINATION OF AWARDS 

3.1 Selection of Participants. The Administrator, in its sole discretion, shall select the Employees who shall be Participants for any
Performance Period. Participation in the Plan is in the sole discretion of the Administrator and shall be determined Performance Period by Performance Period. Accordingly, an Employee who is a Participant for a given Performance Period is in no way
assured of being selected for participation in any subsequent Performance Period. 
 3.2 Determination of Performance Period. The
Administrator, in its sole discretion, shall establish whether a Performance Period shall be a Fiscal Year or such longer or shorter period of time. The Performance Period may differ from Participant to Participant and from award to award. 

3.3 Determination of Performance Goals. The Administrator shall establish the Performance Goals for each Participant for the Performance
Period, and the Administrator (or its designee) shall communicate the applicable Performance Goals to each Participant. The Performance Goals may differ from Participant to Participant and from award to award. 

3.4 Determination of Target Awards. The Administrator shall establish a Target Award for each Participant for each Performance Period,
and the Administrator (or its designee) shall communicate the applicable Target Award to each Participant. 
 3.5 Determination of Payout
Formula or Formulae. The Administrator will establish a Payout Formula or Formulae for purposes of determining the Actual Award (if any) payable to each Participant. Each Payout Formula may (a) be based on a comparison of actual performance
to the Performance Goals, (b) provide for the payment of a Participant’s Target Award if the Performance Goals for the Performance Period are achieved at the predetermined level and (c) provide for the payment of an Actual Award
greater than or less than the Participant’s Target Award, depending upon the extent to which actual performance exceeds or falls below the Performance Goals, subject to the limitations in Section 3.7. 

3.6 Determination of Actual Awards. After the end of each Performance Period, the Administrator will determine the extent to which the
Performance Goals applicable to each Participant for the Performance Period were achieved or exceeded. The Actual Award for each Participant will be determined by applying the Payout Formula to the level of actual performance that has been
determined by the Administrator; provided that notwithstanding anything to the contrary in this Plan, the Administrator may (a) reduce or eliminate the Actual 

  
 3 

 
Award that otherwise would be payable under the Payout Formula; (b) increase the Actual Award; or (c) determine whether or not any Participant will receive an Actual Award in the event
that the Participant incurs a Termination of Employment before such Actual Award is to be paid pursuant to Section 4.1. If a Participant’s Actual Award is reduced or eliminated, no other Participant’s Actual Award shall be increased
as a result. The Administrator has the absolute discretion to reduce or eliminate payment of an Actual Award if in the Administrator’s judgment corporate performance, financial condition, individual performance, general economic conditions, or
other similar factors make such reduction or elimination appropriate. 
 3.7 Maximum Actual Awards. The Administrator may establish
the maximum amount or value of the Actual Award paid to any Participant for any Performance Period. 
 ARTICLE 4. PAYMENT OF AWARDS

 4.1 Right to Receive Payment. A Participant shall have no right to receive an Actual Award unless the Participant is employed
by the Company or an Affiliate on the date of payment, unless otherwise determined by the Administrator. 
 4.2 Unfunded Plan. Each
Actual Award that may become payable under the Plan shall be paid solely from the general assets of the Company or the Affiliate that employs the Participant (as the case may be), as determined by the Company. No amounts awarded or accrued under the
Plan shall be funded, set aside or otherwise segregated prior to payment. The obligation to pay Actual Awards under the Plan shall at all times be an unfunded and unsecured obligation of the Company. Participants shall have the status of general
creditors of the Company or the Affiliate that employs the Participant. 
 4.3 Timing of Payment. Subject to Sections 3.7 and
4.6, payment of each Actual Award shall be made as soon as administratively practicable after the end of the applicable Performance Period, but in any event no later than required to ensure that that no amount paid or to be paid hereunder shall be
subject to the provisions of Section 409A(a)(1)(B) of the Code. 
 4.4 Form of Payment. Each Actual Award shall be paid in cash
(or its equivalent) or in Share-based awards (or a combination thereof) in a single lump sum, except as otherwise determined by the Administrator. To the extent an Actual Award is paid in whole or in part in the form of Share-based awards, such
awards shall be granted under an equity incentive plan maintained by the Company for the payment or awarding of Shares. 
 4.5 Payment in
the Event of Death. If a Participant dies before receiving an Actual Award that was scheduled to be paid before his or her death for a prior Performance Period, then the Actual Award shall be paid to the Participant’s designated beneficiary
or, if no beneficiary has been designated, to the administrator or representative of his or her estate, subject to applicable law. Any beneficiary designation or revocation of a prior designation shall be effective only if it is in writing, signed
by the Participant and received by the Company prior to the Participant’s death, subject to applicable law. 

  
 4 

 4.6 Recoupment Policy. All awards granted under the Plan shall be subject to any Company
recoupment or clawback policy, as in effect from time to time, including any required by Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act. 

ARTICLE 5. ADMINISTRATION 

5.1 Administrator Authority. The Plan shall be administered by the Administrator, subject to Section 5.3; provided, however,
that with respect to any Executive, the Committee shall act as Administrator. The Administrator shall have all powers and discretion necessary or appropriate to administer the Plan and to control its operation, including (without limitation) the
power to (a) determine which Employees shall be granted awards, (b) prescribe the terms and conditions of the awards, (c) interpret the Plan, (d) adopt such procedures and sub-plans as are
necessary or appropriate, (e) adopt rules for the administration, interpretation and application of the Plan and (f) interpret, amend or revoke any such rules. 

5.2 Decisions Binding. All determinations and decisions made by the Administrator, the Board or any delegate of the Administrator
pursuant to the provisions of the Plan shall be final, conclusive and binding on all persons and shall be given the maximum deference permitted by law. 

5.3 Delegation by the Administrator. The Administrator, on such terms and conditions as it may provide, may delegate all or part of its
authority and powers under the Plan to one or more directors and/or employees of the Company, except that the Committee may not delegate its authority and powers under the Plan with respect to Executives. 

ARTICLE 6. GENERAL PROVISIONS 

6.1 Tax Withholding. The Company or an Affiliate, as applicable, shall withhold all required taxes from an Actual Award, including any
federal, state, local or other taxes. 
 6.2 Application of Section 409A. The provisions of this Plan are intended
to be exempt from the requirements of Section 409A of the Code so that none of the payments to be provided under this Plan will be subject to the additional tax imposed under Section 409A of the Code, and any ambiguities herein will be
interpreted to be so exempt. In no event will the Administrator reimburse Participants for any taxes that may be imposed as result of Section 409A of the Code. 

6.3 No Effect on Employment. Neither the Plan nor any Target Award shall confer upon a Participant any right with respect to continuing
the Participant’s employment with the Company or an Affiliate. Nothing in the Plan shall interfere with or limit in any way the right of the Company or an Affiliate, as applicable, to terminate any Participant’s employment or service at
any time, with or without cause. The Company and its Affiliates expressly reserve the right, which may be exercised at any time and without regard to when during or after a Performance Period such exercise occurs, to terminate any individual’s
employment with or without cause, and to treat him or her without regard to the effect that such treatment might have upon him or her as a Participant. 

  
 5 

 6.4 Participation; No Effect on Other Benefits. No Employee shall have the right to be
selected to receive an award under the Plan, or, having been so selected, to be selected to receive a future award. Except as expressly set forth in a Participant’s employment agreement with the Company or an Affiliate, any Actual Awards under
the Plan shall not be considered for the purpose of calculating any other benefits to which such Participant may be entitled, including (a) any termination, severance, redundancy or end-of-service payments, (b) other bonuses or long-service awards, (c) overtime premiums, (d) pension or retirement benefits or (e) future Base Salary or any other payment to be made by
the Company to such Participant. All Participants expressly acknowledge that there is no obligation on the part of the Company to continue the Plan. Any Actual Awards granted under the Plan are not intended to be compensation of a continuing or
recurring nature, or part of a Participant’s normal or expected compensation, 
 6.5 Successors. All obligations of the Company
and any Affiliate under the Plan, with respect to awards granted hereunder, shall be binding on any successor to the Company and/or such Affiliate, whether the existence of such successor is the result of a merger, consolidation, direct or indirect
purchase of all or substantially all of the business or assets of the Company or such Affiliate, or any similar transaction. 
 6.6
Nontransferability of Awards. No award granted under the Plan shall be sold, transferred, pledged, assigned or otherwise alienated or hypothecated, other than by will, by the laws of descent and distribution or to the limited extent provided
in Section 4.5. All rights with respect to an award granted to a Participant shall be available during his or her lifetime only to the Participant. 

ARTICLE 7. DURATION, AMENDMENT AND TERMINATION 

7.1 Duration of the Plan. The Plan shall remain in effect until terminated pursuant to Section 7.2. 

7.2 Amendment, Suspension or Termination. The Board or the Administrator may amend, suspend or terminate the Plan, or any part thereof,
at any time and for any reason; provided that this Plan may not be suspended or terminated, nor amended in a manner adverse to a Participant for a period of twelve (12) months following a Change in Control of the Company. No award may be
granted during any period of suspension or after termination of the Plan. 
 ARTICLE 8. LEGAL CONSTRUCTION 

8.1 Severability. In the event any provision of the Plan shall be held illegal or invalid for any reason, the illegality or invalidity
shall not affect the remaining parts of the Plan, and the Plan shall be construed and enforced as if the illegal or invalid provision had not been included. 

8.2 Requirements of Law. The granting of awards under the Plan shall be subject to all applicable laws, rules and regulations, and to
such approvals by any governmental agencies or national securities markets as may be required. 
 8.3 Captions. Captions are provided
herein for convenience only and shall not serve as a basis for interpretation or construction of the Plan.   

  
 6 

 APPENDIX A 

PERFORMANCE METRICS 
 The Administrator
may establish Performance Goals derived from the following metrics, or from such other measures of performance selected by the Administrator from time to time: 
  

	 	•	 	acquisitions of assets or intellectual property 

  

	 	•	 	appreciation in and/or maintenance of any publicly-traded securities of the Company 

  

	 	•	 	cash flow return on investment 

  

	 	•	 	cash flow, cash balance or cash flow per share (before or after dividends) 

  

	 	•	 	cash margin 

  

	 	•	 	clinical achievements (including initiating clinical studies, initiating or completing enrollment or enrolling particular numbers of subjects in clinical studies) 

 

	 	•	 	comparisons with various stock market indices 

  

	 	•	 	completing phases of a clinical study (including the enrollment phase, dose-escalation or dose-expansion phase or announcing or presenting preliminary or final data from clinical studies, in each case, whether on
particular timelines or generally) 

  

	 	•	 	debt reduction 

  

	 	•	 	development of manufacturing processes (including initiating or completing formulation development work, validating API or drug product processes or achieving certain specifications) 

 

	 	•	 	development of new product candidates 

  

	 	•	 	drug development milestones 

  

	 	•	 	earnings or loss per share 

  

	 	•	 	earnings or losses (including earnings or losses before taxes, before interest and taxes, or before interest, taxes, depreciation and amortization) 

 

	 	•	 	economic value added (or an equivalent metric) 

  

	 	•	 	employee satisfaction 

  

	 	•	 	employee survey results 

  

	 	•	 	establishing relationships with commercial entities with respect to the marketing, distribution and sale of the Company’s products (including with group purchasing organizations, distributors and other vendors)

  

	 	•	 	expense or cost reduction 

  

	 	•	 	financial ratios, including those measuring liquidity, activity, profitability or leverage 

  

	 	•	 	financing and other capital raising transactions (including sales of the Company’s equity or debt securities) 

  

	 	•	 	gross margin 

  

	 	•	 	gross profits 

  

	 	•	 	implementation, completion or attainment of measurable objectives with respect to research (including nominating a development candidate, initiating a new discovery program, initiation or completion of preclinical
characterization of a product candidate, or initiation or completion of IND-enabling studies) 

  
 7 

	 	•	 	improvement in or attainment of expense levels or working capital levels, including cash, inventory and accounts receivable 

  

	 	•	 	launch of new products or approvals of existing products in new indications 

  

	 	•	 	market share 

  

	 	•	 	net income or loss (before or after taxes) 

  

	 	•	 	net operating income or profits, before or after tax 

  

	 	•	 	net sales 

  

	 	•	 	operating cash flow or other operating efficiencies 

  

	 	•	 	operating income (before or after taxes) 

  

	 	•	 	operating margin 

  

	 	•	 	passing pre-approval inspections (whether of the Company or the Company’s third-party manufacturer, if any) and achieving or maintaining other quality-related regulatory
requirements 

  

	 	•	 	pricing and/or reimbursement approval 

  

	 	•	 	recruiting and maintaining personnel 

  

	 	•	 	reductions in costs 

  

	 	•	 	regulatory achievements (including submitting or filing applications or other documents with regulatory authorities, or clearing or receiving approval of any such applications or other documents) 

 

	 	•	 	return on assets, net assets, investment or capital employed (including return on total capital or return on invested capital) 

  

	 	•	 	return on equity or average stockholders’ equity 

  

	 	•	 	return on operating revenue 

  

	 	•	 	revenue, revenue growth or product revenue growth 

  

	 	•	 	sales or licenses of the Company’s assets, including its intellectual property 

  

	 	•	 	share price 

  

	 	•	 	stockholders’ equity 

  

	 	•	 	strategic partnerships or transactions (including in-licensing and out-licensing of intellectual property, whether in a particular
jurisdiction or territory or globally or through partnering transactions) 

  

	 	•	 	supply chain achievements (including establishing relationships with manufacturers or suppliers of component materials and/or the Company’s products or product candidates) 

 

	 	•	 	total stockholder return 

  

	 	•	 	working capital 

  

	 	•	 	year-end cash 

 In the areas of development, regulatory progress and
commercialization, the achievements described above performed by a third party with which the Company has a licensing or collaborative agreement (a “Partner”) may apply to the Company, if so determined by the Administrator. For example, if
a Partner accomplishes development milestones, regulatory achievements, commercialization or sales targets with an asset within a program that is a subject of the licensing or collaboration agreement between the Company and the Partner, then such
Partner’s accomplishments may constitute achievements of the Company. 

  
 8 

 Performance Goals may be based solely by reference to the Company’s performance or the performance of a
subsidiary, division, business segment or business unit of the Company, or based upon the relative performance of other companies or upon comparisons of any of the indicators of performance relative to other companies. 

The Administrator may adjust the results under any performance criterion to exclude any of the following events that occurs during a performance measurement
period: (a) asset write-downs, (b) litigation, claims, judgments or settlements, (c) the effect of changes in tax law, accounting principles or other such laws or provisions affecting reported results, (d) accruals for
reorganization and restructuring programs, (e) any extraordinary, unusual or non-recurring items, (f) exchange rate effects for non-U.S. dollar denominated net
sales and operating earnings or (g) statutory adjustments to corporate tax rates. 
 Any Performance Goal used may be measured (a) in absolute
terms, (b) in relative terms, including (without limitation) the passage of time and/or against other companies or metrics, (c) on a per-share basis, (d) against the performance of the Company
as a whole or against particular segments or products of the Company and/or (e) on a pre-tax or after-tax basis. Any Performance Goal may be measured on a basis
other than generally accepted accounting principles. 

  
 9EX-10.14

 Exhibit 10.14 

ARCUS BIOSCIENCES, INC. 

SEVERANCE AND CHANGE IN CONTROL AGREEMENT 

This Severance and Change in Control Agreement (the “Agreement”) is made and entered into by and between
                 (“Executive”) and Arcus Biosciences, Inc., a Delaware corporation (the “Company”), effective as of the
date specified in Section 1 below. 
 This Agreement provides severance and acceleration benefits in connection with certain qualifying
terminations of Executive’s employment with the Company. 
 Certain capitalized terms are defined in Section 8. 

The Company and Executive agree as follows: 

1. Term. This Agreement shall become effective on the date on which it is signed by Executive (the “Effective
Date”). 
 2. Certain Involuntary Termination Benefits. 

(a) Involuntary Termination Following a Change in Control. If Executive is subject to an Involuntary Termination that occurs within
twelve months following a Change in Control and Executive satisfies the conditions described in Section 2(b) below, then: 
 (i) the
Company shall continue to pay such Executive’s Base Salary for a period of six months following such Executive’s Separation, generally in accordance with the Company’s standard payroll procedures; 

(ii) the Company shall pay the Executive a lump-sum cash amount equal to Executive’s annual
target bonus established by the Company for the fiscal year in which Executive’s Separation occurs, prorated based on the number of days that Executive was employed by the Company during such fiscal year; 

(iii) If Executive timely elects continued coverage under COBRA, the Company shall pay the same portion of the monthly premium under COBRA as
it pays for active employees and their eligible dependents until the earliest of (a) the last day of the period ending on the date that is 6 months following such Executive’s Separation, (b) the expiration of Executive’s
continuation coverage under COBRA or (c) the date when Executive becomes eligible for substantially equivalent health insurance coverage in connection with new employment. Notwithstanding the foregoing, if the Company determines in its sole
discretion that it cannot provide the foregoing subsidy of COBRA coverage without potentially violating or causing the Company to incur additional expense as a result of noncompliance with applicable law (including, without limitation,
Section 2716 of the Public Health Service Act), the Company instead will pay Executive a taxable monthly payment in an amount equal to the monthly COBRA premium that Executive would be required to pay to continue the group health coverage in
effect on the date of Executive’s Separation for Executive and Executive’s eligible dependents 

 
pursuant to the Company’s health insurance plans in which Executive or Executive’s eligible dependents participated as of the day of Executive’s Separation (which amount shall be
based on the premium for the first month of COBRA coverage), which payments shall be made regardless of whether Executive elects COBRA continuation coverage; and 

(iv) Executive shall vest in all of Executive’s remaining unvested equity awards. 

(b) Preconditions to Severance and Vesting Acceleration Benefits / Timing of Benefits. As a condition to Executive’s receipt of any
benefits described in Section 2(a), Executive shall execute and allow to become effective a general release of claims in substantially the form attached hereto and, if requested by the Company’s Board of Directors, must immediately resign
as a member of the Company’s Board of Directors and as a member of the board of directors of any subsidiaries of the Company. Executive must execute and return the release on or before the date specified by the Company, which will in no event
be later than 50 days after Executive’s employment terminates. If Executive fails to return the release by the deadline or if Executive revokes the release, then Executive will not be entitled to the benefits described in this Section 2.
All such benefits will be provided, paid or commence within 60 days after Executive’s Involuntary Termination (and, where applicable, will include at such time any amounts accrued from the date of Executive’s Separation). If such 60-day period spans two calendar years, then such benefit will in any event be provided, paid or commence in the second calendar year. 

3. Section 409A. The Company intends that all payments and benefits provided under this Agreement or otherwise are exempt from, or
comply with, with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) so that none of the payments or benefits will be subject to the additional tax imposed under Code
Section 409A, and any ambiguities herein will be interpreted in accordance with such intent. For purposes of Code Section 409A, each payment, installment or benefit payable under this Agreement is hereby designated as a separate payment.
In addition, if the Company determines that Executive is a “specified employee” under Code Section 409A(a)(2)(B)(i) at the time of Executive’s Separation, then (i) any severance payments or benefits, to the extent that they
are subject to Code Section 409A, will not be paid or otherwise provided until the first business day following the earlier of (A) expiration of the six-month period measured from Executive’s
Separation or (B) the date of Executive’s death and (ii) any installments that otherwise would have been paid or provided prior to such date will be paid or provided in a lump sum when the severance payments or benefits commence. 

4. Section 280G. 
 (a)
Notwithstanding anything contained in this Agreement to the contrary, in the event that the payments and benefits provided pursuant to this Agreement, together with all other payments and benefits received or to be received by Executive
(“Payments”), constitute “parachute payments” within the meaning of Code Section 280G, and, but for this Section 4, would be subject to the excise tax imposed by Code Section 4999 (the
“Excise Tax”), then the Payments shall be made to Executive either (i) in full or (ii) as to such lesser amount as would result in no portion of the Payments being subject to the Excise Tax (a “Reduced
Payment”), 

  
 -2- 

 
whichever of the foregoing amounts, taking into account applicable federal, state and local income taxes and the Excise Tax, results in Executive’s receipt on an after-tax basis, of the greatest amount of benefits, notwithstanding that all or some portion of the Payments may be subject to the Excise Tax. For the avoidance of doubt, the Payments shall include acceleration of
vesting of equity awards granted by the Company that vest based on service to the Company and that accelerate in connection with a Change in Control of the Company, but only to the extent such acceleration of vesting is deemed a parachute payment
with respect to a Change in Control of the Company. 
 (b) For purposes of determining whether to make a Reduced Payment, if applicable, the
Company shall cause to be taken into account all federal, state and local income and employment taxes and excise taxes applicable to the Executive (including the Excise Tax). If a Reduced Payment is made, the Company shall reduce or eliminate the
Payments in the following order, unless (to the extent permitted by Section 409A of the Code) Executive elects to have the reduction in payments applied in a different order: (1) cancellation of accelerated vesting of options with no
intrinsic value, (2) reduction of cash payments, (3) cancellation of accelerated vesting of equity awards other than options, (4) cancellation of accelerated vesting of options with intrinsic value and (5) reduction of other
benefits paid to the Executive. In the event that acceleration of vesting is reduced, such acceleration of vesting shall be cancelled in the reverse order of the date of grant of the Executive’s equity awards. In the event that cash payments or
other benefits are reduced, such reduction shall occur in reverse order beginning with payments or benefits which are to be paid farthest in time from the date of the determination. For avoidance of doubt, an option will be considered to have no
intrinsic value if the exercise price of the shares subject to the option exceeds the fair market value of such shares. 
 (c) All
determinations required to be made under this Section 4 (including whether any of the Payments are parachute payments and whether to make a Reduced Payment) will be made by a nationally recognized independent accounting firm selected by the
Company. For purposes of making the calculations required by this section, the accounting firm may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonably, good faith interpretations concerning the
application of Code Sections 280G and 4999. The Company will bear the costs that the accounting firm may reasonably incur in connection with the calculations contemplated by this Section 4. The accounting firm’s determination will be
binding on both Executive and the Company absent manifest error. 
 (d) As a result of uncertainty in the application of Sections 4999 and
280G of the Code at the time of the initial determination by the accounting firm hereunder, it is possible that payments will have been made by the Company which should not have been made (an “Overpayment”) or that additional
payments which will not have been made by the Company could have been made (an “Underpayment”), consistent in each case with the calculation of whether and to what extent a Reduced Payment shall be made hereunder. In either
event, the accounting firm shall determine the amount of the Underpayment or Overpayment that has occurred. In the event that the accounting firm determines that an Overpayment has occurred, the Executive shall promptly repay, or transfer, to the
Company the amount of any such Overpayment; provided, however, that no amount shall be payable, or transferable, by the Executive to the Company if and to the extent that such payment or transfer would not reduce the

  
 -3- 

 
amount that is subject to taxation under Section 4999 of the Code. In the event that the accounting firm determines that an Underpayment has occurred, such Underpayment shall promptly be
paid or transferred by the Company to or for the benefit of the Executive, together with interest at the applicable federal rate provided in Section 7872(f)(2) of the Code. 

(e) If this Section 4 is applicable with respect to an Executive’s receipt of a Reduced Payment, it shall supersede any contrary
provision of any plan, arrangement or agreement governing the Executive’s rights to the Payments. 
 5. Company’s
Successors. Any successor to the Company or to all or substantially all of the Company’s business and/or assets shall assume the Company’s obligations under this Agreement and agree expressly to perform the Company’s obligations
under this Agreement in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession. 

6. Miscellaneous Provisions. 

(a) Modification or Waiver. No provision of this Agreement may be modified, waived or discharged unless the modification, waiver or
discharge is agreed to in writing and signed by Executive and by an authorized officer of the Company (other than Executive). No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the
other party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time. 
 (b)
Integration. This Agreement represents the entire agreement and understanding between the parties as to the subject matter herein and supersedes all prior or contemporaneous agreements, whether written or oral, with respect to the subject
matter of this Agreement. 
 (c) Choice of Law. The validity, interpretation, construction and performance of this Agreement shall be
governed by the internal substantive laws, but not the conflicts of law rules, of the State of California. 
 (d) Tax Withholding. Any
payments provided for hereunder are subject to reduction to reflect applicable withholding and payroll taxes and other reductions required under federal, state or local law. 

(e) Notices. Any notice required by the terms of this Agreement shall be given in writing. It shall be deemed effective upon
(i) personal delivery, (ii) deposit with the United States Postal Service, by registered or certified mail, with postage and fees prepaid or (iii) deposit with nationally recognized overnight courier, with shipping charges prepaid.
Notice shall be addressed to the Company at its principal executive office (attention General Counsel) and to Executive at the address that he or she most recently provided to the Company in accordance with this Subsection (e). 

  
 -4- 

 (f) Severability. The invalidity or unenforceability of any provision or provisions of
this Agreement shall not affect the validity or enforceability of any other provision hereof, which shall remain in full force and effect. 

(g) Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together
will constitute one and the same instrument. 
 7. At-Will Employment. Nothing contained in
this Agreement shall (a) confer upon Executive any right to continue in the employ of the Company, (b) constitute any contract or agreement of employment, or (c) interfere in any way with the
at-will nature of Executive’s employment with the Company. 
 8. Definitions. The
following terms referred to in this Agreement shall have the following meanings: 
 (a) “Base Salary” means
Executive’s annual base salary as in effect immediately prior to an Involuntary Termination; provided, however, that in the event of a Resignation for Good Reason due to a material reduction in Executive’s base salary, “Base
Salary” means Executive’s annual base salary as in effect immediately prior to such reduction. 
 (b)
“Cause” means Executive’s (i) unauthorized use or disclosure of the Company’s confidential information or trade secrets, which use or disclosure causes material harm to the Company, (ii) material breach of
any agreement with the Company, (iii) material failure to comply with the Company’s written policies or rules, (iv) conviction of, or plea of “guilty” or “no contest” to, a felony under the laws of the United
States or any State, (v) gross negligence or willful misconduct, (vi) continuing failure to perform assigned duties after receiving written notification of the failure from the Company or its Board of Directors or (vii) failure to
cooperate in good faith with a governmental or internal investigation of the Company or its directors, officers or employees, if the Company has requested such cooperation. 

(c) “Change in Control” means (i) a sale, conveyance or other disposition of all or substantially all of the
assets, property or business of the Company, except where such sale, conveyance or other disposition is to a wholly owned subsidiary of the Company, (ii) a merger or consolidation of the Company with or into another corporation, entity or
person, other than any such transaction in which the holders of voting capital stock of the Company outstanding immediately prior to the transaction continue to hold a majority of the voting capital stock of the Company (or the surviving or
acquiring entity) outstanding immediately after the transaction (taking into account only stock of the Company held by such stockholders immediately prior to the transaction and stock issued on account of such stock in the transaction), or
(iii) the direct or indirect acquisition (including by way of a tender or exchange offer) by any person, or persons acting as a group, of beneficial ownership or a right to acquire beneficial ownership of shares representing a majority
of the voting power of the then outstanding shares of capital stock of the Company; provided, however, that a Change in Control shall not include any transaction or series of related transactions (1) principally for bona
fide equity financing purposes or (2) effected exclusively for the purpose of changing the domicile of the Company. A series of related transactions shall be deemed to constitute a single transaction for purposes of

  
 -5- 

 
determining whether a Change in Control has occurred. In addition, if a Change in Control constitutes a payment event with respect to any amount that is subject to Code Section 409A, then
the transaction must also constitute a “change in control event” as defined in Treasury Regulation Section 1.409A-3(i)(5) to the extent required by Code Section 409A. 

(d) “COBRA” means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended. 

(e) “Involuntary Termination” means either Executive’s (i) Termination without Cause or (ii) Resignation
for Good Reason. 
 (f) “Resignation for Good Reason” means a Separation as a result of Executive’s resignation
from employment within 12 months after one of the following conditions has come into existence without Executive’s consent: (i) a reduction in Executive’s annual Base Salary by more than 10%, other than a general reduction that is
part of a cost-reduction program that affects all similarly situated employees in substantially the same proportions, (ii) a relocation of Executive’s principal workplace by more than 25 miles from its location prior to such Change in
Control or (iii) a material reduction of responsibilities, authority or duties, provided that neither a mere change in title alone nor reassignment following a Change in Control to a position that is similar to the position held prior to the
Change in Control shall constitute a material reduction in job responsibilities. A Resignation for Good Reason will not be deemed to have occurred unless the employee gives the Company written notice of the condition within 90 days after the
condition comes into existence and the Company fails to remedy the condition within 30 days after receiving such written notice. 
 (g)
“Separation” means a “separation from service” as defined in the regulations under Code Section 409A. 

(h) “Termination Without Cause” means a Separation as a result of the termination of Executive’s employment by the
Company without Cause, provided the individual is willing and able to continue performing services within the meaning of Treasury Regulation 1.409A-1(n)(1). 

  
 -6- 

 IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company
by its duly authorized officer, as of the day and year indicated below. 
  

			
	COMPANY

 
			
		
	By:	 	 
	Name:	 	  

	Title:	 	  

	Date:	 	  

 
			
	
	EXECUTIVE

 
			
		
	By:	 	 
	Name:	 	  

	Date:	 	  

  
 -7- 

 GENERAL RELEASE OF ALL CLAIMS 

In consideration of the severance benefits to be paid
to                     (“Executive”) by Arcus Biosciences, Inc. (the “Company”), as described in Paragraph 1 below, Executive, on
Executive’s own behalf and on behalf of Executive’s heirs, executors, administrators and assigns, to the fullest extent permitted by applicable law, hereby fully and forever releases and discharges the Company and its directors, officers,
employees, agents, successors, predecessors, subsidiaries, parent, shareholders, employee benefit plans and assigns (together called “the Releasees”), from all known and unknown claims and causes of action including, without limitation,
any claims or causes of action arising out of or relating in any way to Executive’s employment with the Company, including the termination of that employment. 

1. If Executive signs [(and does not revoke)] this General Release of All Claims (“Release”), the Company will provide Executive with
the severance benefits described in Section         of the Severance and Change in Control Agreement, dated                  ,
20    , between the Company and Executive (the “Severance Agreement”). 
 2. Executive’s Company equity
awards, to the extent vested (for the avoidance of doubt, including pursuant to the Severance Agreement) and outstanding as of Executive’s employment termination date, will be treated as provided in the applicable equity plan and the related
award agreements. Such agreements will remain in effect in accordance with their terms, and Executive acknowledges that Executive will remain bound by them. Any Company equity awards that are unvested as of Executive’s employment termination
date will be automatically forfeited, and Executive will have no further rights to such awards. Executive acknowledges that the enclosed report accurately reflects a summary of Executive’s outstanding equity awards. 

3. Executive understands and agrees that this Release is a full and complete waiver of all claims including, without limitation, claims of
wrongful discharge, constructive discharge, breach of contract, breach of the covenant of good faith and fair dealing, harassment, retaliation, discrimination, violation of public policy, defamation, invasion of privacy, interference with a leave of
absence, personal injury or emotional distress and claims under Title VII of the Civil Rights Act of 1964, the Fair Labor Standards Act, the Equal Pay Act of 1963, the Americans With Disabilities Act, the Civil Rights Act of 1866, the Age
Discrimination in Employment Act of 1967 (ADEA), the California Labor Code, the California Fair Employment and Housing Act, the California Family Rights Act, the Family Medical Leave Act or any other federal or state law or regulation relating to
employment or employment discrimination. Executive further understands and agrees that this waiver includes all claims, known and unknown, to the greatest extent permitted by applicable law. However, this release covers only those claims that arose
prior to the execution of this Release. Execution of this Release does not bar any claim that arises hereafter, including (without limitation) a claim for breach of this Release. In addition, this Release does not cover any claim for indemnification
Executive may have pursuant to the Company’s bylaws, [Executive’s Indemnification Agreement dated             ] or applicable law or Executive’s right to coverage under any
applicable D&O insurance policy with the Company. 
 4. Executive also hereby agrees that nothing contained in this Release shall
constitute or be treated as an admission of liability or wrongdoing by the Releasees or Executive. 

  
 -8- 

 5. In addition, Executive hereby expressly waives any and all rights and benefits conferred upon
Executive by the provisions of Section 1542 of the Civil Code of the State of California, which states as follows: 
 A general release
does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor. 

6. If any provision of this Release is found to be unenforceable, it shall not affect the enforceability of the remaining provisions and the
court shall enforce all remaining provisions to the full extent permitted by law. 
 7. This Release constitutes the entire agreement between
Executive and Releasees with regard to the subject matter of this Release. It supersedes any other agreements, representations or understandings, whether oral or written and whether express or implied, which relate to the subject matter of this
Release. Executive understands and agrees that this Release may be modified only in a written document signed by Executive and a duly authorized officer of the Company. 

8. Executive understands and agrees that the Company shall have no obligation to provide to Executive any severance benefits described in the
Severance and Change in Control Agreement unless and until Executive has complied with the requirements described in Section 2(b) of the Severance and Change in Control Agreement, including executing this Release within the time period
specified in Paragraph 13 below. 
 9. Executive understands and agrees that at all times in the future Executive shall remain bound by
Executive’s Proprietary Information and Inventions Agreement, a copy of which is enclosed herewith. [List any other agreements that should survive termination of employment.] 

10. [Executive agrees not to disclose to others the terms of the Severance Agreement or this Release, except that Executive may disclose such
information to Executive’s spouse and to Executive’s attorney or accountant in order for such attorney or accountant to render services to Executive related to the Employment Agreement or this Release.] 

11. Executive agrees that Executive will never make any disparaging statements (orally or in writing) about the Company or its stockholders,
directors, officers, employees, products, services or business practices. The Company agrees to instruct its officers and directors not to disparage Executive in any manner likely to be harmful to Executive’s personal or business reputation.
Nothing in this Section 11 is intended to, and shall not, prohibit the Executive and the Company (and its officers and directors) from responding accurately and fully to any question, inquiry or request for information when required by legal
process. 
 12. This Release shall be governed by and its provisions interpreted under the laws of the state of California. 

  
 -9- 

 13. [Executive understands that Executive has the right to consult with an attorney before
signing this Release. Executive also understands that Executive has 21 days after receipt of this Release to review and consider this Release, discuss it with an attorney of Executive’s own choosing, and decide whether to execute it or not.
Executive also understands that Executive may revoke this Release during a period of 7 days after Executive signs it and that this Release will not become effective until after the 7-day revocation period has
expired (and then only if Executive has not revoked this Release). In order to revoke this Release, within 7 days after Executive executes this Release Executive must deliver to
                     at the Company a letter stating that Executive is revoking it. Executive understands that if Executive chooses to revoke this
Release within 7 days after Executive signs it, Executive will not receive any severance benefits and the Release will have no effect.] [Executive has          days after receipt of this Release to review and
consider this Release, discuss it with an attorney of Executive’s own choosing, and decide whether to execute it or not.] 

  
 -10- 

 14. Executive states that before signing this Release, Executive: 

 

	 	•	 	Has read it, 

  

	 	•	 	Understands it, 

  

	 	•	 	Knows that he or she is giving up important rights, 

  

	 	•	 	Is aware of his or her right to consult an attorney before signing it, and 

  

	 	•	 	Has signed it knowingly and voluntarily. 

  

							
	Date:	 	  
	 		  	  

				
		 		 		  	Signature
				
		 		 		  	  
 Print Full Name

 Enclosures: 
 Equity
Report 
 Proprietary Information and Inventions Agreement 

[Indemnification Agreement] 
 [LIST ANY OTHERS] 

  
 -11-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}]]